Pioneering Scalable Solutions In AAV Manufacturing And Testing For Gene Therapy

Gene therapy holds immense potential for curing genetic disorders, but its widespread adoption and availability are impeded by obstacles in scalability and testing. The conventional methods of producing adeno-associated virus (AAV) vectors, which deliver therapeutic genes to patients' cells, are both costly and inefficient.

WuXi Advanced Therapies' groundbreaking Tetracycline-Enabled Self-Silencing Adenovirus (TESSA®) technology is enabling the production of AAV vectors at a Good Manufacturing Practice (GMP) grade without the need for transfection. This revolutionary technology slashes costs and complexity, while simultaneously enhancing yields and patient safety. In addition to this, WuXi Advanced Therapies also offers a comprehensive development and testing platform to ensure the quality and safety of gene therapies.

This advancement is crucial for the broader accessibility and efficacy of gene therapies. Learn how pharmaceutical and biotech companies can leverage this cutting-edge technology to bring transformative gene therapies to market, making treatments more readily available to patients worldwide.